Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder

Cancer

Volumn 118, Issue 1, 2012, Pages 72-81

  Scosyrev, Emil ^a   Messing, Edward M ^a   Van Wijngaarden, Edwin ^a   Peterson, Derick R ^a   Sahasrabudhe, Deepak ^b   Golijanin, Dragan ^a   Fisher, Susan G ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

gemcitabine and cisplatin; locally advanced bladder cancer; neoadjuvant chemotherapy; pathologic down staging

Indexed keywords

CISPLATIN; GEMCITABINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER UROTHELIAL CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; COHORT ANALYSIS; CYSTECTOMY; DRUG RESPONSE; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 83855162903     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26238     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Stenzl A, Cowan NC, De Santis M, et al. Guidelines on bladder cancer: muscle-invasive and metastatic. Arnheim, The Netherlands: European Association of Urology; 2008: 56.
3. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-675. (Pubitemid 32120143)
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005; 48: 202-205.
5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866. (Pubitemid 37025405)
6. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999; 354: 533-540.
7. Weight CJ, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Cancer. 2009; 115: 792-799.
8. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
9. Dalbagni G, Genega E, Hashive M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001; 165: 1111-1116. (Pubitemid 32210214)
10. Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. Cancer. 2008; 113: 2471-2477.
11. Cheung YB,. A modified least-squares regression approach to the estimation of risk difference. Am J Epidemiol. 2007; 166: 1337-1344. (Pubitemid 350129422)
12. Agresti A,. Categorical data analysis. 2nd ed. New York: John Wiley & Sons, Inc.; 2002: 145-146, 267-314.
13. Cox D,. Regression models and life tables. J Royal Stat Soc 1972; B34: 187.
14. Prentice R, Kalbfleisch J, Peterson A, Flournoy N, Farewell V, Breslow N,. The analysis of failure times in the presence of competing risks. Biometrics. 1978; 34: 541-554. (Pubitemid 9067879)
15. Marubini E, Valsecchi M,. Analysing survival data from clinical trials and observational studies. New York: John Wiley & Sons, Inc.; 1995: 171-181, 192, 235, 346.
16. Scosyrev E, Ely BW, Messing EM, et al. Do mixed histologic features affect survival benefit from neo-adjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? BJU Int. (In press).
17. Sonpavde G, Goldman BH, Speights VO,. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009; 115: 4104-4109.
18. Bolenz C, Herrmann E, Bastian PJ, et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int. 2010; 106; 493-499.
19. Herr WH, Donat SM, Bajorin DF,. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol. 2001; 165: 811-814. (Pubitemid 32156284)
20. Nieuwenhuijzen JA, Bex A, Meinhardt W, et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol. 2005; 174: 80-85.